» Articles » PMID: 38705383

A Novel Role for the Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Delta Isoform in Hepatocellular Proliferation

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2024 May 5
PMID 38705383
Authors
Affiliations
Soon will be listed here.
Abstract

The phosphatidylinositol-4,5-bisphosphate 3-kinase delta isoform (Pik3cd), usually considered immune-specific, was unexpectedly identified as a gene potentially related to either regeneration and/or differentiation in animals lacking hepatocellular Integrin Linked Kinase (ILK). Since a specific inhibitor (Idelalisib, or CAL101) for the catalytic subunit encoded by Pik3cd (p110δ) has reported hepatotoxicity when used for treating chronic lymphocytic leukemia and other lymphomas, the authors aimed to elucidate whether there is a role for p110δ in normal liver function. To determine the effect on normal liver regeneration, partial hepatectomy (PHx) was performed using mice in which p110δ was first inhibited using CAL101. Inhibition led to over a 50% decrease in proliferating hepatocytes in the first 2 days after PHx. This difference correlated with phosphorylation changes in the HGF and EGF receptors (MET and EGFR, respectively) and NF-κB signaling. Ingenuity Pathway Analyses implicated C/EBPβ, HGF, and the EGFR heterodimeric partner, ERBB2, as three of the top 20 regulators downstream of p110δ signaling because their pathways were suppressed in the presence of CAL101 at 1 day post-PHx. A regulatory role for p110δ signaling in mouse and rat hepatocytes through MET and EGFR was further verified using hepatocyte primary cultures, in the presence or absence of CAL101. Combined, these data support a role for p110δ as a downstream regulator of normal hepatocytes when stimulated to proliferate.

References
1.
Greenbaum L, Li W, Cressman D, Peng Y, Ciliberto G, Poli V . CCAAT enhancer- binding protein beta is required for normal hepatocyte proliferation in mice after partial hepatectomy. J Clin Invest. 1998; 102(5):996-1007. PMC: 508965. DOI: 10.1172/JCI3135. View

2.
Rozengurt E, Soares H, Sinnet-Smith J . Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther. 2014; 13(11):2477-88. PMC: 4222988. DOI: 10.1158/1535-7163.MCT-14-0330. View

3.
Kiseleva Y, Antonyan S, Zharikova T, Tupikin K, Kalinin D, Zharikov Y . Molecular pathways of liver regeneration: A comprehensive review. World J Hepatol. 2021; 13(3):270-290. PMC: 8006075. DOI: 10.4254/wjh.v13.i3.270. View

4.
Fouraschen S, de Ruiter P, Kwekkeboom J, de Bruin R, Kazemier G, Metselaar H . mTOR signaling in liver regeneration: Rapamycin combined with growth factor treatment. World J Transplant. 2013; 3(3):36-47. PMC: 3832859. DOI: 10.5500/wjt.v3.i3.36. View

5.
Ronald Funk C, Wang S, Chen K, Waller A, Sharma A, Edgar C . PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. Blood. 2022; 139(4):523-537. PMC: 8796652. DOI: 10.1182/blood.2021011597. View